Erratum (Chung-Tsen Hsueh, 14 December 2009)
The corresponding author want to point out there is misplacement of cited referrences 15 and 16 in the final publication. The correct placement is as followed in page 3 of pdf publication.
The European Medicines Agency has recognized these findings, and restricts the use of anti-EGFR antibody in CRC patients only with wild-type KRAS tumors .
National Cancer Institute (NCI) has suspended all ongoing U.S. cooperative group studies involving anti-EGFR antibody in CRC since June 2008 . NCI has amended N0147 study, which is an adjuvant trial comparing cetuximab plus FOLFOX vs. FOLFOX in patients with stage III colon cancer after surgery. After amendment, only patients with wild-type KRAS tumors will be randomized for protocol treatment . read full comment
Comment on: Javle et al. Journal of Hematology & Oncology, 2:9